jmvho, hope you're right. TTTav66's post# 113277 was highlighted again today - Wayne State prof. will be presenting A2-73 remyelination at ECTRIMS/ACTRIMS in Paris on 10/27. Tantalizingly BIIB will be talking about RWE & personalized medicine at the conference, a term that Ariana showcases. Why is BIIB suddenly talking RWE & personalized medicine when they have clunky overpowered tests on weak compounds chasing defunct (beta amyloid) theories? So many threads...
fireman pointed out Klamer talking about MS as recently at CNS Partnering and Deal Making on 9/11.
Last but not least, Biostockclub's post# 122112...
Anavex couldn't possibly have dropped the indication from further testing. It makes the other outcome viable.
News 
Market Data 
Discover 
